- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 20, 2019 P2, N=21, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
Trial completion: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) - Apr 20, 2019 P3, N=260, Completed, Completed --> Terminated; The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years. Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=29, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018
- |||||||||| dobutamine / Generic mfg.
Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, MRI: ECHOBIKE: Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging (clinicaltrials.gov) - Mar 14, 2019 P=N/A, N=124, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2018 Enrolling by invitation --> Completed | Phase classification: P1 --> PN/A | N=80 --> 124 | Trial completion date: Jun 2011 --> Mar 2019 | Trial primary completion date: Jun 2010 --> Feb 2019
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab
Trial completion, Trial completion date: Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 5, 2019 P1/2, N=46, Completed, Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jan 2018
- |||||||||| Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Mar 5, 2019 P2, N=92, Completed, Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jan 2018 Active, not recruiting --> Completed
- |||||||||| Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
Trial completion: Intravenous Immunoglobulin (IVIG) in Lung Transplantation (clinicaltrials.gov) - Mar 5, 2019 P2, N=11, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Campath (alemtuzumab) / Sanofi
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker: ACT-1: Alemtuzumab and CHOP in T-cell Lymphoma (clinicaltrials.gov) - Mar 1, 2019 P3, N=136, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016
- |||||||||| Enrollment closed, Phase classification: A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) - Feb 15, 2019
P2, N=126, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Phase classification: P3 --> P2
- |||||||||| milciclib (TZLS-201) / Tiziana Life Sci
Trial termination: Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma (clinicaltrials.gov) - Feb 6, 2019 P2, N=72, Terminated, Active, not recruiting --> Terminated; For the last patient still on treated nominal therapeutic use of the Milciclib was approved at INT Milano. Active, not recruiting --> Terminated; For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion, Enrollment change, Trial completion date, Combination therapy: Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Feb 5, 2019 P1/2, N=35, Completed, Active, not recruiting --> Terminated; For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano. Active, not recruiting --> Completed | N=56 --> 35 | Trial completion date: Nov 2017 --> Aug 2017
- |||||||||| dasatinib / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 1, 2019 P1/2, N=38, Completed, Active, not recruiting --> Completed | N=56 --> 35 | Trial completion date: Nov 2017 --> Aug 2017 Active, not recruiting --> Completed | Trial completion date: May 2018 --> Dec 2017 | Trial primary completion date: Apr 2018 --> Aug 2016
- |||||||||| Biomarker, Trial completion, Trial completion date: CLEAR: CLL Empirical Antibiotic Regimen (clinicaltrials.gov) - Jan 25, 2019
P2, N=71, Completed, Active, not recruiting-> Completed | N=42 --> 26 Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Mar 2016
- |||||||||| Trial completion, Phase classification: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Jan 24, 2019
P1, N=90, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Completed | Phase classification: PN/A --> P1
- |||||||||| Cytorex EBV (baltaleucel-T) / Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Athenex
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (clinicaltrials.gov) - Jan 14, 2019 P2, N=15, Terminated, Active, not recruiting --> Completed Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Apr 2018 | N=35 --> 15 | Trial completion date: Sep 2019 --> Sep 2018; Insufficient enrollment rate
- |||||||||| Trial completion: Airway Vascular Lesions (clinicaltrials.gov) - Jan 12, 2019
P=N/A, N=75, Completed, Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Apr 2018 | N=35 --> 15 | Trial completion date: Sep 2019 --> Sep 2018; Insufficient enrollment rate Active, not recruiting --> Completed
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Trial completion date, Trial primary completion date: Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab (clinicaltrials.gov) - Jan 11, 2019 P1, N=13, Completed, Trial completion date: Nov 2010 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Jan 2019 | Trial primary completion date: Aug 2019 --> Jan 2019
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients (clinicaltrials.gov) - Jan 11, 2019 P2, N=66, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Jan 2019 | Trial primary completion date: Aug 2019 --> Jan 2019 Trial primary completion date: Sep 2019 --> Aug 2016
- |||||||||| everolimus / Generic mfg., bendamustine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Jan 4, 2019 P1, N=20, Completed, N=50 --> 21 | Trial completion date: Jan 2022 --> Jul 2018 | Recruiting --> Terminated; Insufficient recruitment and unavailability of the treatment Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
|